44 results about "Low pathogenic" patented technology

Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and / or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described. Non-conjugative bacteria limiting exchange of genetic material, and antibody resistant bacteria are also provided.

Chimeric proteins are expressed, secreted or released by a bacterium to immunize against or treat a parasite, infectious disease or malignancy. The delivery vector may also be attenuated, non-pathogenic, low pathogenic, or a probiotic bacterium. The chimeric proteins include chimeras of, e.g., phage coat and / or colicin proteins, bacterial toxins and / or enzymes, autotransporter peptides, lytic peptides, multimerization domains, and / or membrane transducing (ferry) peptides. The active portion of the immunogenic chimeric proteins can include antigens against a wide range of parasites and infectious agents, cancers, Alzheimer's and Huntington's diseases, and have enhanced activity when secreted or released by the bacteria, and / or have direct anti-parasite or infectious agent activity. The activity of the secreted proteins is further increased by co-expression of a protease inhibitor that prevents degradation of the effector peptides. Addition of an antibody binding or antibody-degrading protein further prevents the premature elimination of the vector and enhances the immune response.

It is intended to provide a virus vector by which an exogenous nucleotide sequence can be inserted and easily transferred into a mammalian host cell and a gene encoded by the exogenous nucleotide sequence can be expressed in the host cell, and which has a low risk of pathogenicity and is appropriately usable in gene therapy of mammals. Namely, a recombinant vector originating in HHV-6 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U5, U6, U7, U8, U24, and U25 regions of HHV-6; or a recombinant vector originating in HHV-7 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U7, U8, U24, U24a, and U25 regions of HHV-7.

The invention relates to a real-time fluorescent RCR molecular detection kit for leptosphaeria maculans, which contains a general hybrid reagent for gene expression, ddH2O, a probe and primer mixture and a positive control. The probe and primer mixture contains 5mumol / L of LMpro probe, 18mumol / L of LMf upstream primer and 18mumol / L of LMr downstream primer; and the positive control is 100ng / muL leptosphaeria maculans DNA solution. The kit can directly detect the sick rape seed or plant residues, has the advantages of quickness, sensitivity, accuracy and good repeatability, particularly can beused for detecting a sample with low pathogenic bacteria content, is particularly suitable for quickly detecting the leptosphaeria maculans in seeds, plants and sick residues of cruciferous crops such as imported and exported rape seeds and the like, and has good application prospect.

The invention relates to a low-pathogenicity porcine reproductive and respiratory syndrome virus (PRRSV), and a vaccine and an application thereof. The PRRSV is separated from porcine lung tissues by using Marc-145 cells, the above separated strain can proliferate on the Marc-145 cells and make the Marc-145 cells have typical cytopathy, the Marc-145 is detected to obtain the tilter of the separated strain of 10<7.0> TCID50 / mL, and the strain is preserved in China General Microbiological Culture Collection Center on Oct. 22, 2015 with the preservation number of CGMCC No.9819; and leaned piglets artificially inoculated with the new virus strain only have weak thermal response, have no obvious clinic symptoms, and normally grow without untoward effects. The new strain artificially inoculated to pigs can induce the pigs to have good immune response I order to generate high level PRRSV antibodies.

The invention discloses a reagent and method for highly pathogenic H7 avian influenza virus detection and application of the reagent. The reagent for highly pathogenic H7 avian influenza virus detection in the present application comprises a primer pair and / or a probe. The primer pair and / or the probe is designed for a specific recognition sequence of highly pathogenic H7 avian influenza virus. The specific recognition sequence is a sequence shown in Seq ID No. 1, or a reverse complementary sequence of the sequence shown in Seq ID No. 1, or a synonymous mutation sequence of the sequence shown in Seq ID No. 1 or the reverse complementary sequence of the sequence shown in Seq ID No. 1, or a sequence substituted with 1-4 bases. The reagent in the present application can effectively distinguish the highly pathogenic H7 avian influenza virus from low pathogenic H7 avian influenza virus, thereby providing technical support and guidance for timely taking effective prevention and control measures, and reducing economic losses in livestock and poultry industry due to a failure in distinguishing between high pathogenicity and low pathogenicity of the H7 avian influenza virus.